Lu L - Search Results

1

Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Yao L, Jia G, Lu L, Ma W. Yao L, et al. Among authors: lu l. Curr Oncol. 2022 Jul 12;29(7):4902-4913. doi: 10.3390/curroncol29070389. Curr Oncol. 2022. PMID: 35877249 Free PMC article. Review.

2

Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.

Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Lu L, et al. Oncol Res. 2007;16(8):395-403. doi: 10.3727/000000006783980892. Oncol Res. 2007. PMID: 17913048

3

Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome.

Lu L, Zhang C, Zhu G, Irwin M, Risch H, Menato G, Mitidieri M, Katsaros D, Yu H. Lu L, et al. Breast Cancer Res. 2011 Jun 6;13(3):R56. doi: 10.1186/bcr2893. Breast Cancer Res. 2011. PMID: 21645396 Free PMC article.

4

Circulating tumor cell clusters-associated gene plakoglobin and breast cancer survival.

Lu L, Zeng H, Gu X, Ma W. Lu L, et al. Breast Cancer Res Treat. 2015 Jun;151(3):491-500. doi: 10.1007/s10549-015-3416-1. Epub 2015 May 10. Breast Cancer Res Treat. 2015. PMID: 25957595 Review.

5

IFNγ enhances cytotoxic efficiency of the cytotoxic T lymphocytes against human glioma cells.

Shao S, Risch E, Burner D, Lu L, Minev B, Ma W. Shao S, et al. Among authors: lu l. Int Immunopharmacol. 2017 Jun;47:159-165. doi: 10.1016/j.intimp.2017.04.003. Epub 2017 Apr 12. Int Immunopharmacol. 2017. PMID: 28410529

6

Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses.

Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W. Li H, et al. Among authors: lu l. Immunology. 2017 Nov;152(3):462-471. doi: 10.1111/imm.12783. Epub 2017 Jul 27. Immunology. 2017. PMID: 28664991 Free PMC article.

7

BRCA1 mRNA expression modifies the effect of T cell activation score on patient survival in breast cancer.

Lu L, Huang H, Zhou J, Ma W, Mackay S, Wang Z. Lu L, et al. BMC Cancer. 2019 Apr 25;19(1):387. doi: 10.1186/s12885-019-5595-3. BMC Cancer. 2019. PMID: 31023256 Free PMC article.

8

Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.

Yao L, Jia G, Lu L, Bao Y, Ma W. Yao L, et al. Among authors: lu l. Int Immunopharmacol. 2020 Aug;85:106628. doi: 10.1016/j.intimp.2020.106628. Epub 2020 May 28. Int Immunopharmacol. 2020. PMID: 32474388 Review.

9

Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients.

Yao L, Lu L, Ma W. Yao L, et al. Among authors: lu l. Heliyon. 2022 Apr;8(4):e09302. doi: 10.1016/j.heliyon.2022.e09302. Epub 2022 Apr 26. Heliyon. 2022. PMID: 35497026 Free PMC article. Review.

10

Efficacy, Safety, and Challenges of CAR T-Cells in the Treatment of Solid Tumors.

Chen Q, Lu L, Ma W. Chen Q, et al. Among authors: lu l. Cancers (Basel). 2022 Dec 3;14(23):5983. doi: 10.3390/cancers14235983. Cancers (Basel). 2022. PMID: 36497465 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18,009 results

Search Page

Filters